Super High Contrast USPIO-Enhanced Cerebrovascular Angiography Using Ultrashort Time-to-Echo MRI
Open Access
- 13 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Biomedical Imaging
- Vol. 2024, 1-10
Abstract
Background. Ferumoxytol (Ferahame, AMAG Pharmaceuticals, Waltham, MA) is increasingly used off-label as an MR contrast agent due to its relaxivity and safety profiles. However, its potent T2 relaxivity limits achievable T1-weighted positive contrast and leads to artifacts in standard MRI protocols. Optimization of protocols for ferumoxytol deployment is necessary to realize its potential. Methods. We present first-in-human clinical results of the Quantitative Ultrashort Time-to-Echo Contrast Enhanced (QUTE-CE) MRA technique using the superparamagnetic iron oxide nanoparticle agent ferumoxytol for vascular imaging of the head/brain in 15 subjects at 3.0T. The QUTE-CE MRA method was implemented on a 3T scanner using a stack-of-spirals 3D Ultrashort Time-to-Echo sequence. Time-of-flight MRA and standard TE T1-weighted (T1w) images were also collected. For comparison, gadolinium-enhanced blood pool phase images were obtained retrospectively from clinical practice. Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and intraluminal signal heterogeneity (ISH) were assessed and compared across approaches with Welch’s two-sided -test. Results. Fifteen volunteers ( years old, 9 women) participated. QUTE-CE MRA provided high-contrast snapshots of the arterial and venous networks with lower intraluminal heterogeneity. QUTE-CE demonstrated significantly higher SNR ( ), blood-tissue CNR ( ), and lower ISH ( ) compared to ferumoxytol T1-weighted ( ; ; , respectively) and time-of-flight ( ; ; , respectively), with in each comparison. The high CNR increased the depth of vessel visualization. Vessel lumina were captured with lower heterogeneity. Conclusion. Quantitative Ultrashort Time-to-Echo Contrast-Enhanced MR angiography provides approximately 5-fold superior contrast with fewer artifacts compared to other contrast-enhanced vascular imaging techniques using ferumoxytol or gadolinium, and to noncontrast time-of-flight MR angiography, for clinical vascular imaging. This trial is registered with NCT03266848.Keywords
Funding Information
- Northeastern University (1R41DA043974-01)
- National Institutes of Health (1R41DA043974-01)
This publication has 32 references indexed in Scilit:
- Ferumoxytol-enhanced ultrashort TE MRA and quantitative morphometry of the human kidney vasculatureAbdominal Radiology, 2021
- Comparison of gadolinium‐enhanced and ferumoxytol‐enhanced conventional and UTE‐MRA for the depiction of the pulmonary vasculatureMagnetic Resonance in Medicine, 2019
- Noncontrast MR angiography: An updateJournal of Magnetic Resonance Imaging, 2018
- Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of RadiologistsCanadian Association of Radiologists Journal, 2018
- Gibbs‐ringing artifact removal based on local subvoxel‐shiftsMagnetic Resonance in Medicine, 2015
- Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in childrenPediatric Radiology, 2014
- Quantitative contrast‐enhanced MRI with superparamagnetic nanoparticles using ultrashort time‐to‐echo pulse sequencesMagnetic Resonance in Medicine, 2014
- An image-based modeling framework for patient-specific computational hemodynamicsMedical & Biological Engineering & Computing, 2008
- MR angiography with blood pool contrast agentsEuropean Radiology, 2007
- Multimodal Image Coregistration and Partitioning—A Unified FrameworkNeuroImage, 1997